HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 739 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR COVID-19 Takes the Life of a Widowed Mother of 6 Who... March 20, 2020 Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... December 19, 2023 Two-Time Breast Cancer Warrior Left Devastated After Package Full of Meds... June 25, 2020 EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... April 7, 2022 Load more HOT NEWS The American Society of Clinical Oncology and the American Cancer Society:... Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas
